Taraxasterol

Taraxasterol is a pentacyclic triterpenoid compound isolated from Taraxacum mongolicum. Taraxasterol is an LXRα activator, with metabolic and anti-inflammatory effects. Taraxasterol may be used in research on immune-inflammatory diseases[1][2][3].

Product Specifications

CAS Number

[1059-14-9]

UNSPSC

12352211

Hazard Statement

H302, H315, H319, H335

Target

Interleukin Related; LXR

Type

Natural Products

Related Pathways

Immunology/Inflammation; Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/taraxasterol.html

Purity

99.41

Solubility

DMSO : 1 mg/mL (ultrasonic; heat to 80°C) |Ethanol : 4 mg/mL (ultrasonic)

Smiles

CC(C)([C@]1([H])CC[C@@]([C@](CC[C@@](CC2)3C)4C)5C)[C@@H](O)CC[C@]1(C)[C@@]5([H])CC[C@]4([H])[C@@]3([H])[C@H](C)C2=C

Molecular Formula

C30H50O

Molecular Weight

426.72

Precautions

H302, H315, H319, H335

References & Citations

[1]Zhang X, et al. Effects of taraxasterol on inflammatory responses in lipopolysaccharide-induced RAW 264.7 macrophages. J Ethnopharmacol. 2012 May 7;141 (1) :206-11.|[2]Sang R, Yu Y, Ge B, Xu L, Wang Z, Zhang X. Taraxasterol from Taraxacum prevents concanavalin A-induced acute hepatic injury in mice via modulating TLRs/NF-κB and Bax/Bc1-2 signalling pathways. Artif Cells Nanomed Biotechnol. 2019;47 (1) :3929-3937. |[3]Zheng F, et al. Anti-inflammatory effects of taraxasterol on LPS-stimulated human umbilical vein endothelial cells[J]. Inflammation, 2018, 41: 1755-1761.|[4]San Z, et al. Protective effect of taraxasterol on acute lung injury induced by lipopolysaccharide in mice[J]. International Immunopharmacology, 2014, 19 (2) : 342-350.|[5]Piao T, et al.Taraxasterol inhibits IL-1β-induced inflammatory response in human osteoarthritic chondrocytes. Eur J Pharmacol. 2015 Jun 5;756:38-42.|[6]Movahhed M, et al. Anti-metastatic effect of taraxasterol on prostate cancer cell lines. Res Pharm Sci. 2023 Jun 1;18 (4) :439-448.